Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
HK$ 2.35
Key Takeaways
Risk factor
Very high price volatility
Data is available to registered users only
Data is available to registered users only
Profitability factor
Very low or no dividends
Data is available to registered users only
Data is available to registered users only
About
BioDlink International Co., Ltd. is clinical stage biopharmaceutical company, which engages in developing and commercializing oncology drugs and therapies. Its product portfolio includes: TAB008, TOZ309, TAA013, TAE020, TAB 014, and TAC020. The company was founded on December 4, 2009 and is headquartered in Suzhou, China.
Company Valuation
Considering past and projected metrics, the stock is slightly 'cheaper' than its peers. In particular, the stock is reasonably priced on P/E, of fair value on EV/EBITD.
Data is available to registered users only
Target Price
The average target price of 1875.HK is 2.4 and suggests 1% upside potential. Usually, this means a HOLD recommendation among investment firms. This neutral recommendation
Data is available to registered users only
